Search Results 591-600 of 21524 for Inhibition

1. Desvenlafaxine (oral route) - Mayo Clinic

   It belongs to a group of medicines known as serotonin and norepinephrine reuptake inhibitors (SNRIs). ... inhibitor. Wait 7 days after stopping ...

2. A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy - Mayo Clinic

   ... inhibitor and an IMiD(r) or immunomodulatory agent (e.g., thalidomide, lenalidomide). Induction therapy and following stem cell transplant are considered a ...

3. Publications - Monica R. Flores Navarro, M.D. - Mayo Clinic

   ... inhibitors. Eur J Haematol. 2021 May; 106 (5):682-688 Epub 2021 Feb 17. View ... Risk of bleeding and significant thrombocytopenia in cancer patients treated with ...

4. Neurodermatitis - Diagnosis and treatment - Mayo Clinic

   A calcineurin inhibitor may be helpful in easing itching in sensitive areas such as the genitals. Corticosteroid injections. Your health care provider may ...

5. BRCA Gene Test Clinical Trials - Mayo Clinic Research

   ... inhibitor). Inherited Breast Cancer Study Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL. The purpose of this study is to improve the interpretation ...

6. An Extension Study of Oral Ozanimod for Moderately-to-Severely Active Crohn's Disease - Mayo Clinic

   CYP2C8 inhibitors (eg, gemfibrozil or clopidogrel) and inducers (eg, rifampicin);; Monoamine oxidase inhibitors (eg, selegiline, phenelzine). Exclusions ...

7. A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens - Mayo Clinic

   Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality of life ...

8. Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA) - Mayo Clinic

   Cytochrome P450 3A4 isozyme strong inhibitor: 5 elimination half-lives; · CYP3A strong or moderate inducers: 4 weeks; · Systemic anticancer therapy or ...

9. In the Loop: Experimental Stent Stems Danger of Major Artery Rupture - Mayo Clinic News Network

   Read more In the Loop stories. Mayo Clinic Minute: Cell Study Offers Important Insight on Aging · Mayo Clinic Minute: Balancing Proton Pump Inhibitor Risks and ...

10. First In Human (FIH) Study of REGN5459 in Patients With Relapsed or Refractory Multiple Myeloma (MM) - Mayo Clinic

    including a proteasome inhibitor, an Immunomodulatory imide drug (IMiD), and an ... refractory" to a proteasome inhibitor and an IMiD, or intolerance of therapy.